Savara Inc (NASDAQ:SVRA) Director Buys $59,000.00 in Stock

Savara Inc (NASDAQ:SVRA) Director Joseph S. Mccracken bought 20,000 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was acquired at an average cost of $2.95 per share, for a total transaction of $59,000.00. Following the acquisition, the director now directly owns 210,837 shares of the company’s stock, valued at $621,969.15. The trade was a 10.48 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Savara Trading Up 3.7 %

Savara stock opened at $3.36 on Friday. The company has a 50 day moving average price of $3.76 and a 200 day moving average price of $4.13. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. Savara Inc has a 52 week low of $2.82 and a 52 week high of $5.70. The firm has a market capitalization of $576.64 million, a price-to-earnings ratio of -7.81 and a beta of 1.02.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). Research analysts forecast that Savara Inc will post -0.45 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. HC Wainwright dropped their price target on shares of Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. Evercore ISI reiterated an “in-line” rating and set a $5.00 price objective (down previously from $7.00) on shares of Savara in a research note on Wednesday, November 13th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $9.00 target price on shares of Savara in a research note on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Savara has an average rating of “Moderate Buy” and a consensus price target of $10.17.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of SVRA. CANADA LIFE ASSURANCE Co acquired a new position in shares of Savara during the 1st quarter worth about $35,000. Choreo LLC acquired a new stake in Savara during the second quarter valued at approximately $59,000. DRW Securities LLC acquired a new stake in shares of Savara in the 2nd quarter valued at $62,000. Virtu Financial LLC acquired a new stake in shares of Savara during the third quarter worth approximately $67,000. Finally, Principal Financial Group Inc. boosted its stake in Savara by 64.4% in the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after purchasing an additional 6,973 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.